Weight Watchers has expanded its Med+ offering to include Novo Nordisk's FDA-approved Ozempic pill (semaglutide), a once-daily oral GLP-1 treatment for adults with type 2 diabetes. This addition provides members with a new medication option supported by clinical guidance, insurance navigation, and comprehensive diabetes care tools. The Ozempic pill complements Weight Watchers' existing diabetes support program, which includes tailored nutrition, coaching, and blood sugar tracking. This move aims to enhance member access to effective diabetes management within a clinically supported framework.
Novo Nordisk has initiated a share repurchase programme worth up to DKK 15 billion, starting from February 4, 2026, and running for 12 months. As of May 22, 2026, the company has repurchased over 17 million B shares at an average price of DKK 262.22 ...
Novo Nordisk's POSEIDON study of 18,904 patients across 18 countries found that 40% of people with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or heart failure have cardiovascular inflammation. This inflammation, mea...
The global Bioprocess Automation Software market, valued at $1.67 billion in 2025, is projected to grow to $6.19 billion by 2035 at a 14% CAGR. This growth is fueled by the increasing demand for personalized medicine, flexible manufacturing processes...
The European Medicines Agency's CHMP has recommended marketing authorization for Novo Nordisk's Wegovy 7.2 mg single-dose pen for obesity treatment in the EU. Clinical trials showed an average weight loss of 20.7% in obese patients, with about one-th...
Eli Lilly's experimental obesity drug retatrutide achieved a 28% body weight loss over 80 weeks in a pivotal phase III trial, surpassing Novo Nordisk's leading treatments Wegovy and Ozempic. While retatrutide shows higher efficacy, it also has a high...
